Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks

Cancer Genomics and Proteomics

Volumn 8, Issue 6, 2011, Pages 289-306

  Timms, John F ^a   Menon, Usha ^a   Devetyarov, Dmitry ^b   Tiss, Ali ^c   Camuzeaux, Stephane ^a   Mccurrie, Katherine ^a   Nouretdinov, Ilia ^b   Burford, Brian ^b   Smith, Celia ^c   Gentry Maharaj, Aleksandra ^a   Hallett, Rachel ^a   Ford, Jeremy ^a   Luo, Zhiyuan ^b   Vovk, Volodya ^b   Gammerman, Alex ^b   Cramer, Rainer ^c   Jacobs, Ian ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF READING   (United Kingdom)

Author keywords

Biomarkers; CA125; Connective tissue activating peptide III; CTAPIII; Early diagnosis; MALDI MS serum profiling; Ovarian cancer; PF4; Platelet factor 4

Indexed keywords

BETA THROMBOGLOBULIN; CA 125 ANTIGEN; THROMBOCYTE FACTOR 4;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DOWN REGULATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY CANCER; PEPTIDE ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 81855227600     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. IARC. GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide in 2008. http://globocan.iarc.fr/. Accessed in 2011.
2. CRUK. Cancer statistics: Ovarian cancer survival statistics. http://info.cancerresearchuk.org/cancerstats/types/ovary/survival/. Accessed in 2011.
3. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M and Jacobs I: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10: 327-340, 2009.
4. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR and Buys SS: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113: 775-782, 2009.
5. Brioschi PA, Irion O, Bischof P, Bader M, Forni M and Krauer F: Serum CA 125 in epithelial ovarian cancer. A longitudinal study. Br J Obstet Gynaecol 94: 196-201, 1987. (Pubitemid 17036897)
6. Bast RC, Jr., Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I and Lu K: New tumor markers: CA 125 and beyond. Int J Gynecol Cancer 15(Suppl 3): 274-281, 2005. (Pubitemid 43096594)
7. Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, Paladini D, Van Calster B, Vergote I, Van Huffel S and Valentin L: Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 31: 681-690, 2008.
8. Fung ET: A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 56: 327-329, 2010.
9. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF, 3rd and Liotta L: Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol 532: 59-68, 2003. (Pubitemid 37176780)
10. Ludwig JA and Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856, 2005. (Pubitemid 41746029)
11. Chatterjee SK and Zetter BR: Cancer biomarkers: knowing the present and predicting the future. Future Oncol 1: 37-50, 2005.
12. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S and Farias-Eisner R: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5: 4589-4596, 2005. (Pubitemid 41739936)
13. Su F, Lang J, Kumar A, Ng C, Hsieh B, Suchard MA, Reddy ST and Farias-Eisner R: Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2: 369-375, 2007.
14. Diamandis EP: Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 3: 367-378, 2004.
15. Coombes KR, Morris JS, Hu J, Edmonson SR and Baggerly KA: Serum proteomics profiling-a young technology begins to mature. Nat Biotechnol 23: 291-292, 2005. (Pubitemid 41094414)
16. Karsan A, Eigl BJ, Flibotte S, Gelmon K, Switzer P, Hassell P, Harrison D, Law J, Hayes M, Stillwell M, Xiao Z, Conrads TP and Veenstra T: Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem 51: 1525-1528, 2005. (Pubitemid 41060893)
17. Villanueva J, Philip J, Chaparro CA, Li Y, Toledo-Crow R, DeNoyer L, Fleisher M, Robbins RJ and Tempst P: Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4: 1060-1072, 2005. (Pubitemid 41208664)
18. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D and Selby PJ: Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 51: 1637-1649, 2005. (Pubitemid 41233099)
19. Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A and Thiery J: Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 51: 973-980, 2005. (Pubitemid 40740877)
20. Findeisen P, Sismanidis D, Riedl M, Costina V and Neumaier M: Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. Clin Chem 57: 2409-2411, 2005. (Pubitemid 41692601)
21. Timms JF, Arslan-Low E, Gentry-Maharaj A, Luo Z, T'Jampens D, Podust VN, Ford J, Fung ET, Gammerman A, Jacobs I and Menon U: Preanalytic influence of sample handling on SELDITOF serum protein profiles. Clin Chem 53: 645-656, 2007. (Pubitemid 46580234)
22. Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, Nelson B, Anderson GL, McIntosh M and Urban N: Effects of blood collection conditions on ovarian cancer serum markers. PLoS One 2: e1281, 2007.
23. Baggerly KA, Morris JS, Edmonson SR and Coombes KR: Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97: 307-309, 2005. (Pubitemid 40310279)
24. Diamandis EP: Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res 66: 5540-5541, 2006.
25. Hortin GL: The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52: 1223-1237, 2006.
26. Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J and Kobayashi R: Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 4: 972-981, 2005. (Pubitemid 40863287)
27. Tiss A, Smith C, Menon U, Jacobs I, Timms JF and Cramer R: A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. Proteomics 10: 3388-3392, 2010.
28. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI and Tempst P: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284, 2006. (Pubitemid 43121812)
29. Gammerman A, Vovk V, Burford B, Nouretdinov I, Luo Z, Chervonenkis A, Waterfield M, Cramer R, Tempst P, Villanueva J, Kabir M, Camuzeaux S, Timms J, Menon U and Jacobs I: Serum proteomic abnormality predating screen detection of ovarian cancer. Computer J 52: 326-333, 2009.
30. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC Jr., Oram D and Jacobs IJ: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23: 7919-7926, 2005. (Pubitemid 46657391)
31. Tiss A, Smith C, Camuzeaux S, Kabir M, Gayther S, Menon U, Waterfield M, Timms J, Jacobs I and Cramer R: Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology. Proteomics 7(Suppl 1): 77-89, 2007. (Pubitemid 351547773)
32. Timms JF, Cramer R, Camuzeaux S, Tiss A, Smith C, Burford B, Nouretdinov I, Devetyarov D, Gentry-Maharaj A, Ford J, Luo Z, Gammerman A, Menon U and Jacobs I: Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Clin Chem 56: 262-2711, 2010.
33. Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat 6: 65-70, 1979.
34. Shi L, Zhang J, Wu P, Feng K, Li J, Xie Z, Xue P, Cai T, Cui Z, Chen X, Hou J, Zhang J and Yang F: Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome Sci 7: 7, 2009.
35. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schutte C, Hauss J, Buchler M and Thiery J: Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 15: 3812-3819, 2009.
36. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O'Briant K, Drescher C and Urban N: Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 102: 26-38, 2010.
37. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L and Wang B: Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 108: 641-651, 2008.
38. Pitteri SJ, Hanash SM, Aragaki A, Amon LM, Chen L, Busald Buson T, Paczesny S, Katayama H, Wang H, Johnson MM, Zhang Q, McIntosh M, Wang P, Kooperberg C, Rossouw JE, Jackson RD, Manson JE, Hsia J, Liu S, Martin L and Prentice RL: Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 1: 121, 2009.
39. Beral V, Doll R, Hermon C, Peto R and Reeves G: Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371: 303-314, 2008.
40. Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A and Cramer R: Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. Int J Gynecol Cancer 20: 1518-1524, 2011.
41. Podust V, Zhang Z, Fung ET, Bast R, Chan DW and Song J: Biomarker for Ovarian and Endometrial Cancer: Hepcidin. United States: Vermilllion, Inc. (Fremont, CA, US), The John Hopkins University (Baltimore, MD, US), Board of Regents, The University of Texas System (Austin, TX, US), 2009.